Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Selection and Usage

Introduction to NSAIDs

The American College of Cardiology recommends ibuprofen (≤1.2 g/day) as the NSAID with the lowest gastrointestinal risk, while celecoxib offers cardiovascular advantages over other NSAIDs when used at a dose of 100 mg twice daily, according to high-quality clinical trial evidence 1.

The American Gastroenterological Association suggests that ibuprofeno ≤1.2 g/día has the lowest gastrointestinal risk based on 12 controlled epidemiological studies 1.
The American College of Gastroenterology states that celecoxib reduces severe gastrointestinal events compared to non-selective NSAIDs 2, 3.
Proton pump inhibitors (PPIs) are as effective as misoprostol in preventing NSAID-induced ulcers and are better tolerated, according to the American Gastroenterological Association 1.

The American Heart Association notes that all NSAIDs increase average blood pressure by 5 mmHg, which is a consideration for patients with hypertension or cardiovascular disease 4.
The American College of Cardiology recommends that patients with high cardiovascular risk should avoid all NSAIDs if possible, and if necessary, use naproxen with a proton pump inhibitor (PPI) as it is considered safer cardiovascularly 4.

The National Kidney Foundation advises that all NSAIDs can cause renal complications, and 2% of patients discontinue NSAIDs due to this reason; patients with established renal disease should avoid NSAIDs 4.
The American Society of Nephrology suggests that celecoxib has a better safety profile in mild to moderate renal insufficiency compared to non-selective NSAIDs 5.

The American College of Rheumatology recommends ibuprofen 1.2 g/day for low gastrointestinal risk; doses above 1.2 g/day increase risk 1.
The American Geriatrics Society suggests that celecoxib should be initiated at low doses (100-200 mg/day) in patients with renal insufficiency 5.

The American College of Cardiology states that all NSAIDs are contraindicated in patients with established congestive heart failure, cirrhosis, platelet defects, or thrombocytopenia, and in late pregnancy (6-8 weeks before term) 4.
The American Society of Hematology advises avoiding the combination of NSAIDs with anticoagulants due to increased bleeding risk; if necessary, monitor INR closely 4.

The American Academy of Family Physicians recommends using the lowest effective dose for the shortest possible duration, and intermittent dosing is preferable to continuous daily use when symptoms are not constant 4, 6.
The American Heart Association suggests that all NSAIDs should be considered as potentially increasing cardiovascular risk, and regular monitoring of blood pressure and renal function is necessary during treatment 2, 3, 4, 5.

The North of England guideline strongly recommends that NSAIDs should be used on a limited "as required" basis, with regular review to reassess the need for continued treatment, prioritizing safety by minimizing cumulative exposure to potential adverse effects 7, 8.
The CDC guideline states that systemic NSAIDs should be used at the lowest effective dosage and shortest duration needed, as risks increase with longer use and higher dosages, directly supporting PRN dosing when symptoms are intermittent 9.

For osteoarthritis with intermittent pain flares, PRN celecoxib is ideal, allowing patients to take 200 mg as needed when pain interferes with function, rather than scheduled daily dosing 9, 10.
For inflammatory conditions like ankylosing spondylitis with continuous active symptoms, daily NSAID treatment during the active disease period is more appropriate, although one controlled trial showed no significant differences between continuous versus on-demand NSAID treatment in ankylosing spondylitis 11.

The American College of Cardiology and other guideline societies are not mentioned, however, the ESCEO/OARSI knee osteoarthritis guidelines recommend that oral NSAIDs should only be used intermittently for the shortest period of time and at the lowest possible dose to control pain 10.

Patients requiring daily pain control who cannot achieve adequate relief with PRN dosing may need scheduled celecoxib, but this should be reassessed regularly, considering switching to acetaminophen or adding non-pharmacologic therapies before committing to daily NSAID use 7, 8.
Topical NSAIDs should be considered first for localized joint pain before systemic agents, according to the CDC and ESCEO/OARSI guidelines 9, 10.
Review of the ongoing need for NSAIDs should be done at least every 6 months, as recommended by the North of England guideline 7, 8.